TY - JOUR
T1 - Recent updates on the development of ganetespib as a Hsp90 inhibitor
AU - Choi, Hyun Kyung
AU - Lee, Kyeong
PY - 2012/11
Y1 - 2012/11
N2 - Heat shock protein 90 (Hsp90) plays a critical role in the maintenance of multiple oncogenic pathways and is a required protein for folding and stability of many oncoproteins that are related to the growth, proliferation, and survival of many kinds of cancers. Ganetespib (STA-9090) is a potent, synthetic, small molecule inhibitor of Hsp90, and its binding to Hsp90 is known to result in the degradation of its client proteins and subsequent death of cancer cells. This article provides a review of ganetespib as one of the leading Hsp90 inhibitors, which is under investigation in a broad range of clinical stages for the treatment of cancer.
AB - Heat shock protein 90 (Hsp90) plays a critical role in the maintenance of multiple oncogenic pathways and is a required protein for folding and stability of many oncoproteins that are related to the growth, proliferation, and survival of many kinds of cancers. Ganetespib (STA-9090) is a potent, synthetic, small molecule inhibitor of Hsp90, and its binding to Hsp90 is known to result in the degradation of its client proteins and subsequent death of cancer cells. This article provides a review of ganetespib as one of the leading Hsp90 inhibitors, which is under investigation in a broad range of clinical stages for the treatment of cancer.
UR - http://www.scopus.com/inward/record.url?scp=84874446994&partnerID=8YFLogxK
U2 - 10.1007/s12272-012-1101-z
DO - 10.1007/s12272-012-1101-z
M3 - Article
C2 - 23212626
AN - SCOPUS:84874446994
SN - 0253-6269
VL - 35
SP - 1855
EP - 1859
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
IS - 11
ER -